Literature DB >> 25666877

Cellular factors modulating the mechanism of tau protein aggregation.

Sarah N Fontaine1, Jonathan J Sabbagh, Jeremy Baker, Carlos R Martinez-Licha, April Darling, Chad A Dickey.   

Abstract

Pathological accumulation of the microtubule-associated protein tau, in the form of neurofibrillary tangles, is a major hallmark of Alzheimer's disease, the most prevalent neurodegenerative condition worldwide. In addition to Alzheimer's disease, a number of neurodegenerative diseases, called tauopathies, are characterized by the accumulation of aggregated tau in a variety of brain regions. While tau normally plays an important role in stabilizing the microtubule network of the cytoskeleton, its dissociation from microtubules and eventual aggregation into pathological deposits is an area of intense focus for therapeutic development. Here we discuss the known cellular factors that affect tau aggregation, from post-translational modifications to molecular chaperones.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25666877      PMCID: PMC4406819          DOI: 10.1007/s00018-015-1839-9

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  248 in total

1.  A case of frontotemporal dementia with tau P301L mutation in the Far East.

Authors:  R Tanaka; T Kobayashi; Y Motoi; M Anno; Y Mizuno; H Mori
Journal:  J Neurol       Date:  2000-09       Impact factor: 4.849

2.  Proteasomal degradation of tau protein.

Authors:  Della C David; Robert Layfield; Louise Serpell; Yolanda Narain; Michel Goedert; Maria Grazia Spillantini
Journal:  J Neurochem       Date:  2002-10       Impact factor: 5.372

3.  Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene.

Authors:  S M Pickering-Brown; A M T Richardson; J S Snowden; A M McDonagh; A Burns; W Braude; M Baker; W-K Liu; S-H Yen; J Hardy; M Hutton; Y Davies; D Allsop; D Craufurd; D Neary; D M A Mann
Journal:  Brain       Date:  2002-04       Impact factor: 13.501

4.  Nuclear tau, a key player in neuronal DNA protection.

Authors:  Audrey Sultan; Fabrice Nesslany; Marie Violet; Séverine Bégard; Anne Loyens; Smail Talahari; Zeyni Mansuroglu; Daniel Marzin; Nicolas Sergeant; Sandrine Humez; Morvane Colin; Eliette Bonnefoy; Luc Buée; Marie-Christine Galas
Journal:  J Biol Chem       Date:  2010-12-03       Impact factor: 5.157

5.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

6.  Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase.

Authors:  D P Hanger; K Hughes; J R Woodgett; J P Brion; B H Anderton
Journal:  Neurosci Lett       Date:  1992-11-23       Impact factor: 3.046

7.  Proteasome-caspase-cathepsin sequence leading to tau pathology induced by prostaglandin J2 in neuronal cells.

Authors:  Lisette T Arnaud; Natura Myeku; Maria E Figueiredo-Pereira
Journal:  J Neurochem       Date:  2009-05-03       Impact factor: 5.372

8.  Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism.

Authors:  Tong Li; Hemant K Paudel
Journal:  Biochemistry       Date:  2006-03-14       Impact factor: 3.162

9.  The conformational ensembles of α-synuclein and tau: combining single-molecule FRET and simulations.

Authors:  Abhinav Nath; Maria Sammalkorpi; David C DeWitt; Adam J Trexler; Shana Elbaum-Garfinkle; Corey S O'Hern; Elizabeth Rhoades
Journal:  Biophys J       Date:  2012-11-07       Impact factor: 4.033

10.  Proteolysis of non-phosphorylated and phosphorylated tau by thrombin.

Authors:  Tetsuaki Arai; Jian-Ping Guo; Patrick L McGeer
Journal:  J Biol Chem       Date:  2004-11-12       Impact factor: 5.157

View more
  23 in total

Review 1.  Prion-like Spreading in Tauopathies.

Authors:  Jacob I Ayers; Benoit I Giasson; David R Borchelt
Journal:  Biol Psychiatry       Date:  2017-04-13       Impact factor: 13.382

Review 2.  Targeting innate immunity for neurodegenerative disorders of the central nervous system.

Authors:  Katrin I Andreasson; Adam D Bachstetter; Marco Colonna; Florent Ginhoux; Clive Holmes; Bruce Lamb; Gary Landreth; Daniel C Lee; Donovan Low; Marina A Lynch; Alon Monsonego; M Kerry O'Banion; Milos Pekny; Till Puschmann; Niva Russek-Blum; Leslie A Sandusky; Maj-Linda B Selenica; Kazuyuki Takata; Jessica Teeling; Terrence Town; Linda J Van Eldik
Journal:  J Neurochem       Date:  2016-09       Impact factor: 5.372

Review 3.  Small-molecule PET Tracers for Imaging Proteinopathies.

Authors:  Chester A Mathis; Brian J Lopresti; Milos D Ikonomovic; William E Klunk
Journal:  Semin Nucl Med       Date:  2017-07-13       Impact factor: 4.446

Review 4.  Amyloidogenesis of Tau protein.

Authors:  Bartosz Nizynski; Wojciech Dzwolak; Krzysztof Nieznanski
Journal:  Protein Sci       Date:  2017-09-13       Impact factor: 6.725

5.  How Does Hyperphopsphorylation Promote Tau Aggregation and Modulate Filament Structure and Stability?

Authors:  Liang Xu; Jie Zheng; Martin Margittai; Ruth Nussinov; Buyong Ma
Journal:  ACS Chem Neurosci       Date:  2016-02-24       Impact factor: 4.418

Review 6.  Signaling pathways and posttranslational modifications of tau in Alzheimer's disease: the humanization of yeast cells.

Authors:  Jürgen J Heinisch; Roland Brandt
Journal:  Microb Cell       Date:  2016-03-25

Review 7.  Chronic traumatic encephalopathy-integration of canonical traumatic brain injury secondary injury mechanisms with tau pathology.

Authors:  Jacqueline R Kulbe; Edward D Hall
Journal:  Prog Neurobiol       Date:  2017-08-26       Impact factor: 11.685

8.  Tau Accumulation, Altered Phosphorylation, and Missorting Promote Neurodegeneration in Glaucoma.

Authors:  Marius Chiasseu; Jorge L Cueva Vargas; Laurie Destroismaisons; Christine Vande Velde; Nicole Leclerc; Adriana Di Polo
Journal:  J Neurosci       Date:  2016-05-25       Impact factor: 6.167

9.  Levistolide A Attenuates Alzheimer's Pathology Through Activation of the PPARγ Pathway.

Authors:  Xiaodan Qu; Peipei Guan; Li Han; Zhanyou Wang; Xueshi Huang
Journal:  Neurotherapeutics       Date:  2020-10-09       Impact factor: 7.620

10.  Dual Mechanism of Toxicity for Extracellular Injection of Tau Oligomers versus Monomers in Human Tau Mice.

Authors:  Giusi Manassero; Michela Guglielmotto; Debora Monteleone; Valeria Vasciaveo; Olena Butenko; Elena Tamagno; Ottavio Arancio; Massimo Tabaton
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.